| Not Yet Recruiting | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia | Phase 3 | 2026-09-01 |
| Not Yet Recruiting | A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia | Phase 3 | 2026-09-01 |
| Not Yet Recruiting | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Ph Phenylketonuria | Phase 1 | 2026-03-01 |
| Withdrawn | A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy Sickle Cell Disease, Nephropathy | Phase 2 | 2026-03-01 |
| Recruiting | A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated Healthy Participants | Phase 1 | 2025-07-07 |
| Recruiting | A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD Sickle Cell Disease | Phase 2 | 2025-05-01 |
| Completed | A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Healthy Participants | Phase 1 | 2024-12-20 |
| Completed | Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants Healthy Participants | Phase 1 | 2024-10-17 |
| Completed | Single and Multiple Ascending Dose Study and Food Effect Study for AG181 Healthy Volunteers | Phase 1 | 2024-02-20 |
| Enrolling By Invitation | A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Pyruvate Kinase Deficiency, Anemia, Hemolytic | Phase 4 | 2023-07-06 |
| Completed | A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Heal Moderate Hepatic Impairment | Phase 1 | 2023-01-10 |
| Active Not Recruiting | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) Myelodysplastic Syndromes | Phase 2 | 2022-11-07 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Defici Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia | Phase 3 | 2022-06-08 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Defici Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia | Phase 3 | 2022-06-06 |
| Active Not Recruiting | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RIS Sickle Cell Disease | Phase 2 / Phase 3 | 2022-02-11 |
| Active Not Recruiting | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia | Phase 3 | 2021-12-20 |
| Active Not Recruiting | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or B Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia | Phase 3 | 2021-11-30 |
| Terminated | Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO) Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Anemia | — | 2021-07-02 |
| Completed | Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008 Pyruvate Kinase Deficiency | — | 2021-07-02 |
| Completed | A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 5 Healthy Volunteers | Phase 1 | 2021-01-06 |
| Completed | A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapiv Healthy Volunteers | Phase 1 | 2020-09-21 |
| Completed | A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunt Healthy Volunteers, Anemia, Sickle Cell | Phase 1 | 2020-07-10 |
| Completed | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Part Healthy Volunteers | Phase 1 | 2020-06-17 |
| Completed | A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants Healthy Volunteers | Phase 1 | 2019-10-02 |
| Completed | A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Healthy Volunteers | Phase 1 | 2019-09-30 |
| Completed | A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Ad Healthy Participants | Phase 1 | 2019-07-15 |
| Completed | Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetic Healthy Volunteers | Phase 1 | 2019-06-20 |
| Terminated | A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma Lymphoma | Phase 1 | 2019-05-24 |
| Completed | A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Healthy Male Participants | Phase 1 | 2019-05-16 |
| Completed | Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348- Pyruvate Kinase Deficiency | Phase 3 | 2019-03-21 |
| Active Not Recruiting | A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participa Thalassemia | Phase 2 | 2019-03-20 |
| Completed | A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Pyruvate Kinase Deficiency, Anemia, Hemolytic | Phase 3 | 2018-08-09 |
| Completed | A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Pyruvate Kinase Deficiency, Anemia, Hemolytic | Phase 3 | 2018-06-26 |
| Completed | A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 Healthy Volunteers | Phase 1 | 2018-05-24 |
| Active Not Recruiting | Pyruvate Kinase Deficiency Global Longitudinal Registry Pyruvate Kinase Deficiency | — | 2018-04-23 |
| Completed | Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma Advanced Solid Tumors, Lymphoma | — | 2018-03-01 |
| Completed | Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Hea Healthy Volunteers | Phase 1 | 2017-10-03 |
| Completed | A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function Hepatic Impairment | Phase 1 | 2017-09-26 |
| Completed | Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origi Healthy, Japanese, Non-Asian | Phase 1 | 2017-08-09 |
| Completed | Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects Healthy | Phase 1 | 2017-03-31 |
| Completed | Drug-Drug Interaction Study of AG120 in Healthy Subjects Healthy | Phase 1 | 2016-06-01 |
| Terminated | A Safety and Tolerability Study of AG-519 in Healthy Subjects Anemia | Phase 1 | 2015-12-01 |
| Completed | Food Effect Study of AG120 in Healthy Subjects Healthy | Phase 1 | 2015-10-01 |
| Completed | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies | Phase 1 | 2015-08-07 |
| Completed | A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency Pyruvate Kinase Deficiency | Phase 2 | 2015-06-26 |
| Completed | Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120 Healthy Volunteers | Phase 1 | 2015-06-01 |
| Completed | Food Effect Study of AG-221 in Healthy Male Subjects Healthy Volunteers | Phase 1 | 2014-08-01 |
| Completed | A Phase I Study of AG-348 in Healthy Volunteers Healthy Volunteer | Phase 1 | 2014-05-01 |
| Completed | A Phase I Study of AG-348 in Healthy Volunteers Healthy Volunteer | Phase 1 | 2014-03-01 |
| Approved For Marketing | Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation Acute Myeloid Leukemia, Relapsed Adult AML, Relapsed Pediatric AML | — | — |